RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63,419 | -54.2% | 8,290 | -55.2% | 0.00% | -60.0% |
| Q2 2023 | $138,330 | +138230.0% | 18,518 | +23.9% | 0.01% | +66.7% |
| Q1 2023 | $100 | +455.6% | 14,944 | +550.0% | 0.00% | +200.0% |
| Q4 2022 | $18 | -100.0% | 2,299 | -85.1% | 0.00% | -66.7% |
| Q3 2022 | $164,000 | +320.5% | 15,411 | +223.6% | 0.00% | +200.0% |
| Q2 2022 | $39,000 | +85.7% | 4,762 | +62.1% | 0.00% | – |
| Q1 2022 | $21,000 | -70.0% | 2,938 | -28.5% | 0.00% | -100.0% |
| Q4 2021 | $70,000 | +400.0% | 4,109 | +607.2% | 0.00% | – |
| Q3 2021 | $14,000 | -84.6% | 581 | -76.9% | 0.00% | -100.0% |
| Q2 2021 | $91,000 | – | 2,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |